<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">FUMET, JEAN-DAVID</style></author><author><style face="normal" font="default" size="100%">VINCENT, JULIE</style></author><author><style face="normal" font="default" size="100%">BENGRINE, LEILA</style></author><author><style face="normal" font="default" size="100%">HENNEQUIN, AUDREY</style></author><author><style face="normal" font="default" size="100%">GRANCONATO, LAURA</style></author><author><style face="normal" font="default" size="100%">PALMIER, REMI</style></author><author><style face="normal" font="default" size="100%">GHIRINGHELLI, FRANÇOIS</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4011-4015</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.14395</style></doi><volume><style face="normal" font="default" size="100%">40</style></volume><issue><style face="normal" font="default" size="100%">7</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX. Patients and Methods: Patients received FOLFIRINOX as first-line regimen were retrospectively identified between January 2016 and January 2019. After disease progression or unacceptable toxicity, patients eligible for second-line therapy were treated in our center by PDGX. Results: During this period, 18 patients received PDGX regimen as second-line therapy. Main grade 3 toxicities were hematologic, which required dose adaptation in 14/18 patients. No toxic death was observed. Median second-line progression-free survival (PFS) and overall survival (OS) were 2,91 and 5,3 months, respectively. Total OS from the initiation of first-line was and 11,9 months. Conclusion: Second-line PDGX regimen after FOLFIRINOX failure is feasible, with notable toxicity profile and is associated with poor clinical outcomes.</style></abstract></record></records></xml>